Targeting the "Undruggable" Driver Protein, KRAS G12D , as Potential Therapy in Prostate Cancer.

In spite of the progress made in the development of KRAS G12C inhibitors, there is still continued interest to develop inhibitors of other KRAS such as KRAS G12D for the treatment of diseases, including prostate cancer, colorectal cancer, and non-small-cell lung cancer. This Patent Highlight provides exemplary compounds having activity as inhibitors of G12D mutant KRAS protein.